Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31540857 | 0.87 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1880390 | 0.86 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| Hydrochloric Acid SCHEMBL31540856 | 0.86 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL26941528 | 0.83 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL27872882 | 0.83 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL4690511 | 0.82 | KMT2A (0.47) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL20531437 | 0.82 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2MDM4 | |
| SCHEMBL15874406 | 0.81 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL4284636 | 0.81 | KMT2A (0.46) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL15874638 | 0.81 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121181655-B | Insect short neuropeptide sNPF analogues and application thereof in pests | 四川轻化工大学 | 2026-05-19 | — | — | CN | disclosed |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025051912-A1 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR INHIBITORS | SANOFI (FR) | 2025-03-13 | — | — | WO | disclosed |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240374585-A1 | EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF | REIN THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-109248323-B | Acylated GLP-1 derivatives | 杭州先为达生物科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-4168121-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115702026-A | Macrocyclic compounds and methods of use thereof | 基因泰克公司 | 2023-02-14 | — | — | CN | disclosed |
| WO-2023283639-A1 | EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF | LUNG THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-11518795-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2022-12-06 | — | — | US | disclosed |
| EP-1670515-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006037810-A2 | PROTRACTED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006037811-A2 | PROTRACTED EXENDIN-4 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006005667-A2 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK A/S (DK) | 2006-01-19 | — | — | WO | disclosed |
| US-20050080119-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2005-04-14 | — | — | US | disclosed |
| WO-2005027978-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2005-03-31 | — | — | WO | disclosed |
| US-20030064921-A1 | Methods and compounds for modulating melanocortin receptor ligand binding and activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-04-03 | — | — | US | disclosed |
| WO-2001085930-A9 | METHODS AND COMPOUNDS FOR MODULATING MELANOCORTIN RECEPTOR LIGAND BINDING AND ACTIVITY | UNIV CALIFORNIA (US) | 2003-02-06 | — | — | WO | disclosed |
| US-6331640-B1 | TREATMENT OF REPERFUSION INJURIES | HOFFMANN-LA ROCHE INC. | 2001-12-18 | — | — | US | disclosed |
| WO-2001085930-A2 | METHODS AND COMPOUNDS FOR MODULATING MELANOCORTIN RECEPTOR LIGAND BINDING AND ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | PAICS, CYCS, LSS | KMT2A 2834/4885FABP5 4000/4885FABP7 2688/4885 |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | KMT2A 2834/4885FABP5 4000/4885FABP7 2688/4885 |
| US-20030064921-A1 | Methods and compounds for modulating melanocortin receptor ligand binding and activity | MC3R, MC4R, MC1R | KMT2A 2717/4885FABP5 524/4885FABP7 231/4885 |
| US-20050080119-A1 | Diaminopropionic acid derivatives | AIFM1, HIF1A, AIFM2 | KMT2A 4000/4885FABP5 469/4885FABP7 70/4885 |
| US-20240374585-A1 | EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF | CFTR, SCNN1G, SCNN1B | KMT2A 3224/4885FABP5 3909/4885FABP7 4044/4885 |
| US-11518795-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | KMT2A 313/4885FABP5 944/4885FABP7 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.